In a subsequent phase I trial, they used early tumor-homing iNSCs (h-iNSCTE) loaded with the prodrug ganciclovir and TRAIL, showing that cytotoxic h-iNSCTE treatment can inhibit the progression and recurrence of GBM.169. Here, TNFSF10 is linked to neoplasm.